Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33493297.
- Also identified by DOI 10.1093/cid/ciab057.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Moderate-to-severe hepatic steatosis in people living with human immunodeficiency virus (HIV) without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir, and raltegravir. Prospective trials are required to establish a causal association. Clinical Trials Registration. NCT02382822.
Medical subject headings
- HIV Infections
- Quinolones